Chikungunya Infection in India: Results of a Prospective Hospital Based Multi-Centric Study

Ray, Pratima; Ratagiri, Vinod H.; Kabra, S. K.; Lodha, Rakesh; Sharma, Sumit; Sharma, Bhawna; Kalaivani, Mani; Wig, Naveet

doi:10.1371/journal.pone.0030025

Cited by 62 publications

(84 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[22][23][24] Though the guidelines say that diarrhea and vomiting are more common in children but this study revealed that a good number of adult patients had these symptoms as well which we can find in other study also. 25,26 In this study lymphopenia was more frequent that is about 91% and thrombocytopenia was less and that is 43%. This is similar with other study where lymphopenia was 87% and thrombocytopenia was 37%.…”

Section: Discussionsupporting

confidence: 45%

Chikungunya Viral Infection Requiring Intensive Care – Experience in a Tertiary Care Hospital in Bangladesh

et al. 2017

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 45%

Chikungunya Viral Infection Requiring Intensive Care – Experience in a Tertiary Care Hospital in Bangladesh

et al. 2017

View full text Add to dashboard Cite

“…A particularly large CHIKV outbreak began in eastern Africa in late 2004 and then spread to Indian Ocean islands, India, and southeast Asia over the next 2 years. Estimates suggest that nearly 2 million people became infected during this outbreak (2,(10)(11)(12)(13)(14)(15).…”

mentioning

confidence: 99%

“…CHIKV genomic RNA is detectable at the time of symptom onset and then declines to undetectable levels within 7 days (5,8,11,13,17,23). In contrast, IgM is not uniformly positive until day 5 after illness onset, with IgG appearing 1 to 2 days after IgM (5,8,24,25).…”

mentioning

confidence: 99%

Chikungunya Virus RNA and Antibody Testing at a National Reference Laboratory since the Emergence of Chikungunya Virus in the Americas

Prince¹,

Seaton²,

Matud³

et al. 2014

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

Since first reported in the Americas in December 2013, chikungunya virus (CHIKV) infections have been documented in travelers returning from the Caribbean, with many cases identified by CHIKV antibody and/or RNA testing at our laboratory. We used our large data set to characterize the relationship between antibody titers and RNA detection and to estimate IgM persistence. CHIKV RNA was measured by nucleic acid amplification and CHIKV IgG/IgM by indirect immunofluorescence. Of the 1,306 samples submitted for RNA testing in January through September 2014, 393 (30%) were positive; for 166 RNA-positive samples, CHIKV antibody testing was also ordered, and 84% were antibody negative. Of the 6,971 sera submitted for antibody testing in January through September 2014, 1,811 (26%) were IgM positive; 1,461 IgM positives (81%) were also IgG positive. The relationship between the CHIKV antibody titers and RNA detection was evaluated using 376 IgM-positive samples (138 with RNA testing ordered and 238 deidentified and tested for RNA). RNA detection showed no significant association with the IgM titer but was inversely related to the IgG titer; 63% of the IgG negative sera were RNA positive, compared to 36% of sera with low IgG titers (1:10 to 1:80) and 16% with IgG titers of >1:160. Using second-sample results from 62 seroconverters, we estimated that CHIKV IgM persists for 110 days (95% confidence interval, 78 to 150 days) after the initial antibody-negative sample. These findings indicate that (i) RNA detection is more sensitive than antibody detection early in CHIKV infection, (ii) in the absence of RNA results, the IgG titer of the IgM-positive samples may be a useful surrogate for viremia, and (iii) CHIKV IgM persists for approximately 4 months after symptom onset. C hikungunya virus (CHIKV) is an alphavirus transmitted from one person to another via mosquitos of the genus Aedes (1-3). Nearly all individuals infected with CHIKV become symptomatic, typically exhibiting fever, rash, and debilitating arthralgia (1-3). Most infected individuals show complete recovery within a few weeks; however, 15 to 60% of patients develop chronic arthralgia, which in turn can lead to arthritic joint damage (2, 4-7). Intrapartum mother-to-child transmission has been documented, with serious neurologic and hemorrhagic complications observed in affected infants (8).Since CHIKV was first identified in 1953 (9), there have been multiple epidemics of CHIKV infections throughout Africa and Asia (2). A particularly large CHIKV outbreak began in eastern Africa in late 2004 and then spread to Indian Ocean islands, India, and southeast Asia over the next 2 years. Estimates suggest that nearly 2 million people became infected during this outbreak (2, 10-15).Because the mosquito vectors for CHIKV transmission are present in tropical and temperate regions worldwide and recently infected travelers moving between areas where CHIKV is endemic and not endemic exhibit high levels of viremia (16), epidemiologists have warned that CHIKV could move into new g...

show abstract

“…A recent prospective cohort study of acute febrile illnesses in children at study sites in several Southeast Asian countries determined that CHIKV infection was responsible for approximately 3-fold higher number of cases compared to dengue viruses [8], although this may be an overestimate due to the limited confirmatory testing performed on anti-CHIKV IgM positive samples. Similar hospital-based studies during 2008-2009 in India identified CHIKV as the cause of almost 50% of acute febrile illnesses in the southern state of Karnataka [9], an area greatly affected by the 2005-2006 epidemics.…”

Section: About the Disease And Pathogenmentioning

confidence: 76%

Status of research and development of vaccines for chikungunya

Smalley

Erasmus

Chesson

et al. 2016

Vaccine

View full text Add to dashboard Cite

Chikungunya virus (CHIKV) is an arthritogenic alphavirus that during the last decade has significantly expanded its geographical range and caused large outbreaks of human disease around the world. Although mortality rates associated with CHIKV outbreaks are low, acute and chronic illnesses caused by CHIKV represent a significant burden of disease largely affecting low and middle income countries. This report summarizes the current status of vaccine development for CHIKV.

show abstract

Chikungunya Infection in India: Results of a Prospective Hospital Based Multi-Centric Study

Cited by 62 publications

References 31 publications

Chikungunya Viral Infection Requiring Intensive Care – Experience in a Tertiary Care Hospital in Bangladesh

Chikungunya Viral Infection Requiring Intensive Care – Experience in a Tertiary Care Hospital in Bangladesh

Chikungunya Virus RNA and Antibody Testing at a National Reference Laboratory since the Emergence of Chikungunya Virus in the Americas

Status of research and development of vaccines for chikungunya

Contact Info

Product

Resources

About